Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodysplasias

A prognostic score for patients with lower risk myelodysplastic syndrome

Leukemia volume 22, pages 538–543 (2008)Cite this article

Abstract

Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We evaluated the characteristics of 856 patients with low or intermediate-1 disease by the International Prognostic Scoring System. Mean follow-up was 19.6 months (range 1–262). Of these patients, 87 (10%) transformed to acute myelogenous leukemia, and 429 (50%) had died. By multivariate analysis, characteristics associated with worse survival (P<0.01) were low platelets, anemia, older age, higher percent of marrow blasts and poor-risk cytogenetics. Although not included in the model, higher ferritin (P=0.007) and β2-microglobulin (P<0.001) levels were associated with worse prognosis. This allowed the development of a scoring system in which patients could be grouped in three categories: category 1 (n=182, 21%) with a median survival of 80.3 months (95% CI 68-NA); category 2 (n=408, 48%) with a median survival of 26.6 months (95% CI 22–32) and category 3 (n=265, 31%) with a median survival of 14.2 months (95% CI 13–18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  Google Scholar 

  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–1432.

    Article  CAS  Google Scholar 

  3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sang G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  Google Scholar 

  4. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.

    Article  CAS  Google Scholar 

  5. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  Google Scholar 

  6. Kantarjian H, Issa JP, Rosenfeld CS, Bennett J, Albitar M, Dipersion J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.

    Article  CAS  Google Scholar 

  7. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  Google Scholar 

  8. Cox D . Regression models and life tables. J R Stat Soc B 1972; 34: 187–220.

    Google Scholar 

  9. Grambsch P, Therneau T . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.

    Article  Google Scholar 

  10. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.

    Article  CAS  Google Scholar 

  11. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E . Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811.

    Article  Google Scholar 

  12. Jadersten M, Malcovati L, Dybedal I, Giovanni M, Invernizzi R, Montgomery S et al. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood 2006; 108: 158a [abstract 521].

    Google Scholar 

  13. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.

    Article  CAS  Google Scholar 

  14. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.

    Article  Google Scholar 

  15. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M . Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood 2003; 102: 1622–1625.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

GG-M is supported in part by a Physician-Scientist Award funded by the Commonwealth Cancer Foundation for Research and a Leukemia and Lymphoma Translational Research Grant no. 6173-07. This work was also supported in part by NCI grant 5P01 CA108631. GG-M designed the study, analyzed data and wrote the manuscript; JS analyzed the data and performed statistical analysis; SF, JC, FR-K, GB, SP, EE analyzed data and helped in the writing of the manuscript; HK analyzed data and wrote the manuscript.

Author information

Authors and Affiliations

  1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    G Garcia-Manero, J Shan, S Faderl, J Cortes, F Ravandi, G Borthakur, W G Wierda, S Pierce, E Estey & H Kantarjian

  2. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J Liu & X Huang

Authors
  1. G Garcia-Manero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Faderl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Ravandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Borthakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W G Wierda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. X Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Garcia-Manero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garcia-Manero, G., Shan, J., Faderl, S. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22, 538–543 (2008). https://doi.org/10.1038/sj.leu.2405070

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405070

Keywords

This article is cited by

Search

Advanced search

Quick links